RecallDepth
Class II Ongoing

Ranitidine Tablets, USP 300 mg, 250-count bottles, NDC 53746-254-02.

This recall is currently active, issued December 18, 2019. It was issued by Amneal Pharmaceuticals, Inc..

Company
Amneal Pharmaceuticals, Inc.
Recall Initiated
November 22, 2019
Posted
December 18, 2019
Recall Number
D-0616-2020
Voluntary / Mandated
Voluntary: Firm initiated
Firm Location
Brookhaven, NY, United States
Official Source
View on FDA website ↗

Reason for Recall

CGMP Deviations: Impurity N-nitrosodimethylamine (NDMA) found in API

Distribution

Product was distributed throughout the United States.

Lot / Code Info

HB04118A 2/2020 HB04218A 2/2020 HB04318A 2/2020 HB04418A 2/2020 HF13518A 6/2020 HF13618A 6/2020 HF13718A 6/2020 HF13818A 6/2020 HK02818A 9/2020 HK02918A 9/2020 HK03018A 9/2020 HK03118A 9/2020 HL08418A 11/2020 HL08518A 11/2020 HL08618A 11/2020 HL08718A 11/2020 HB01419A 1/2021 HB05619A 1/2021 HB05719A 1/2021 HB05819A 1/2021 HB05919A 1/2021 HB06019A 1/2021 HB06119A 1/2021

More recalls by Amneal Pharmaceuticals, Inc.

View all recalls by this company →

Other recent Class II Drug recalls